Skip to Content

Triesence Approval History

FDA Approved: Yes (First approved November 29, 2007)
Brand name: Triesence
Generic name: triamcinolone acetonide
Dosage form: Injectable Suspension
Company: Alcon, Inc.
Treatment for: Temporal Arteritis, Uveitis

Triesence (triamcinolone acetonide) is a synthetic corticosteroid indicated for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Development History and FDA Approval Process for Triesence

DateArticle
Dec  3, 2007Approval Alcon Receives FDA Approval of Triesence Injectable Triamcinolone Suspension for Use in Eye Surgery

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide